Formed in late 2004, Codon Devices is still a relative newcomer to the field. But that hasn’t stopped it from shooting to be a leader in the gene synthesis industry — and with a recent deal with ag biotech Agrivida under its belt, the startup is certainly taking steps toward that goal.

With co-founders including George Church, Drew Endy, Jay Keasling, and Joseph Jacobson, it’s no wonder Codon already has a bevy of customers and has also played a critical role in trying to shape the education and regulatory environment surrounding gene synthesis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.